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Abstract
Background: Oral anticoagulants, in Hungary acenocoumarol being the one exclusively used, have a low therapeutic index
and a high bleeding complication rate. The cytochrome P450 2C9 enzyme plays an important role in their metabolism.
Aim: To investigate the influence of CYP2C9 polymorphism on the occurrence of bleeding complications related to
acenocoumarol therapy.
Methods: Genotyping of 421 patients (183 men and 238 women, mean age 66.2±11.8 years), who had been taking
acenocoumarol for at least 6 months, was performed. Based on patient history and laboratory data, the correlations between
genotype and acenocoumarol dose and bleeding complications were retrospectively analysed. 
Results: In 145 patients bearing alleles with reduced activity (CYP2C9*2 and/or *3), the optimal dose of acenocoumarol was
significantly (p<0.001) lower than in patients with the wild type allele (2.12±0.96 mg/day and 2.90±1.46 mg/day, respectively). 
In comparison with wild type allele patients, the mean daily acenocoumarol dose was lower in the CYP2C9*2 group, and the
lowest in *3 bearers. Although the occurrence of minor bleeding complications in patients with the variant allele was significantly 
(p <0.005) higher (OR=1.99 [CI: 1.20–3.33]) than in other patients, there was no difference in major bleeding complications. 
Conclusions: Patients bearing CYP2C9 alleles with reduced enzymatic activity have a lower acenocoumarol requirement. In
patients with CYP2C9*2 and *3 alleles the frequency of minor bleeding complications and the occurrence of high INR values
were significantly higher, but there was no difference in the rate of major bleedings. 
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Introduction 
Coumarins, acenocoumarol in Hungary, are widely
used for the primary and secondary prevention of
thrombotic events. A low therapeutic index and frequent
bleeding complications are characteristic for these drugs.
Determining the proper therapeutic dose is complicated
by a variety of conditions, such as co-morbidities, age,
other drugs used, diet and pharmacogenetic factors. One
of the latter is polymorphism of the cytochrome P450
CYP2C9 enzyme, which metabolises a wide range of
cardiovascular drugs, including oral anticoagulants and
statins [1, 2].
The enzyme CYP2C9 has three common alleles 
(CYP2C9*1, CYP2C9*2 and CYP2C9*3) and six phenotypes.
The variants CYP2C9*4, CYP2C9*5 and CYP2C9*6 have
been described in non-European subjects. The wild type
CYP2C9*1 allele has normal (100%) enzymatic activity
(assessed for warfarin metabolism), while the CYP2C9*2
(Arg144→Cys) and CYP2C9*3 (Ile359→Leu) alleles have
only 12% and 5% of this activity, respectively [3, 4]. The
rate of bleeding complications is relatively high. The
occurrence of minor complications is 7.6-16.5%, while
that of major ones varies between 1.3% and 2.7% per
hundred patient-years [5, 6].
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The effects of genetic factors on the metabolism of
acenocoumarol are substantially less known than those
of warfarin [7]. It has been shown that the
pharmacokinetics of R-acenocoumarol did not differ
between the genotypes, but the S-acenocoumarol
plasma concentration was significantly higher in
patients who had variant *2 and *3 alleles [8]. In the
work of Tassies et al., the presence of variant alleles
was associated with a lower acenocoumarol dose and
a higher frequency of over-anticoagulation at the
initiation of therapy, but the occurrence of bleeding
complications was not significantly higher [9].
In this study, we investigated the influence of
CYP2C9 polymorphism on acenocoumarol dosing and
the occurrence of bleeding complications related to this
therapy during everyday clinical practice.
Methods
Patients
We studied 421 patients (mean age 67.2±11.8 years)
receiving oral anticoagulant therapy, in whom INR was
controlled in the Central Laboratory of our hospital. The
patients had been taking acenocoumarol for at least 6
months (the mean follow-up time was 56.3±62.8 months,
the maximum 361 months, Table I). There was no
difference between the age of patients with wild type
versus variant alleles (66.6±12.0 vs 68.3±11.2, p=0.164).
The indications for the use of oral anticoagulant therapy
were as follows: 206 patients – atrial fibrillation; 60
– artificial heart valve; 17 – cardiomyopathy; 69 – deep
vein thrombosis; 33 – pulmonary embolism; and 36
– history of multiple thromboembolic events. Written
informed consent was obtained from patients for
participation in the study, genetic investigation and
processing of their data. The frequency of bleedings was
determined by interrogation and revision of clinical and
laboratory data. Epistaxis, macroscopic haematuria, and
gastrointestinal and gynaecological bleeding causing
a significant (>3 g/l) haemoglobin decrease were
considered major bleeding complications, while
microscopic haematuria, fecatest positivity, and epistaxis
causing insignificant change in haemoglobin level were
considered minor bleeding complications. The latter three
and the maximal and minimal INR values, as well as
present and previous maximal and minimal doses of
acenocoumarol were registered.
Laboratory investigations
The analysis of haemoglobin was performed with
the CELL-DYN 3500 SL (Abbott) haematology analyser
using the modified haemiglobincyanide method. INR
values were determined by the STA Compact
automated coagulometer using the Neoplastine CI Plus
kit (Diagnostica Stago, Ansieres, France). Creatinine
concentrations (Jaffe method) were analysed by the
Olympus AU 2700 automated clinical chemistry
analyser, using Olympus System Reagents (Olympus
Diagnostica GmbH, Hamburg, Germany). 
Genotyping was performed by Real-Time
Fluorescence PCR using the LightCycler CYP2C9 Mutation
Detection Kit (Roche Molecular Biochemicals, Mannheim,
Germany) on the Roche LightCycler according to the
manufacturer’s instructions. We used a commercial kit,
which is fully characterised and documented, and fulfils
the requirements of the in vitro Diagnostic Medical Device
(IVD) Directive of the EC (98/79/EC). Details on this kit are




Based on medical history and laboratory data, the
correlations between genotype and acenocoumarol
dose and bleeding complications were retrospectively
analysed. Blood and urine tests and fecatest were
performed at the time of the study in all the patients,
but during the anticoagulation process these were not
routinely done. 
Statistical analysis
Results are presented as mean ± standard deviation
or numbers and percentages. The analysed parameters
were compared using Student’s paired t-test, variance
and correlation analysis, and Kruskal-Wallis and Pearson
χ2 tests where appropriate (SPSS statistical program).
A p value < 0.05 was considered statistically significant.
Results
The frequency distribution for the CYP2C9*1,
CYP2C9*2, and CYP2C9*3 alleles was found to
be 0.814, 0.110, and 0.076, respectively. The frequencies
of the six genotypes in the 421 patients are presented
in Table II. The occurrence of wild type homozygosity
was 65.6% and at least one mutant allele was found
in 34.4% of patients. The mean acenocoumarol dose in
the whole studied group was 2.63±1.37 mg/day. In
the 145 patients bearing alleles with reduced activity
Men Women
Number 183 238
Mean age (years ± SD) 67.6±11.2 66.8±12.2
Follow-up time (months ± SD) 52.7±52.1 59.1±69.9
Table I. Demographic characteristics of the
studied patients
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(CYP2C9*2 and/or CYP2C9*3), the optimal dose was
significantly (p <0.001) lower than in patients with the
wild type allele (2.12±0.96 mg/day and 2.90±1.46
mg/day, respectively; Figure 1). Evaluating separately
the mean daily dose in the patients with variant alleles,
it proved to be 2.10±0.91 in CYP2C9*2 and 1.91±1.05 in
CYP2C9*3 bearers, both significantly lower than that in
CYP2C9*1/*1 wild type patients (p <0.001).
In 180 out of all studied patients the creatinine level
was above the normal value. There was a moderate, but
significant, negative correlation between acenocoumarol
dose and age (–0.257) as well as creatinine level (–0.178).
Table III presents the number of patients with the
occurrence of INR higher than 6 in various genotype
groups. The incidence of high INR was significantly more
frequent in the presence of variant alleles (p=0.021).
The frequency of minor bleeding complications
was 17.3% (38 in 276 wild type, 35 in 145 patients with
variant alleles), and of major ones 3.3% (8 and 6
patients, respectively). Although the occurrence of
minor bleeding complications in patients bearing
variant alleles was significantly (p <0.005) higher (Odds
ratio /OR/=1.99 [Confidence intervals /CI/: 1.20–3.33]),
there was no statistically significant difference in major
bleeding complications. Comparing separately the
frequency of minor bleeding in wild type (14%) and
CYP2C9*2 (27%) or CYP2C9*3 (22%) patients,
a significant difference was found between CYP2C9*1/*1
(wild type) and CYP2C9*2 bearers (p <0.01).
Age was significantly higher in patients with INR
higher than 6 (69.6±11.9 vs 66.1±12.0; p <0.005). Since no
difference was found between the age of patients with
wild type and variant alleles, we believe that age could not
explain differences in the acenocoumarol requirement.
There was no significant correlation between age or renal
function and bleeding complications according to the
different allele frequencies.
In the whole study group, 24 patients were taking
aspirin, 2 were taking other thrombocyte aggregation
inhibitors, 8 non-steroid anti-inflammatory drugs,
and 4 steroid hormones. There was no correlation
between the administration of these drugs and
bleeding complications. 
Discussion
The frequency of usage of oral anticoagulation
therapy is growing continuously. Because of the
relatively low therapeutic index and the frequent
Genotype 1/1 1/2 1/3 2/2 2/3 3/3
Patients (n) 276 78 55 3 9 0
% 65.6 18.5 13.1 0.7 2.1 0
Table II. The frequency of Cyp2C9 genotypes in
the 421 patients
Genotype 1/1 1/2 1/3 2/2 2/3 total
Total number of patients 276 78 55 3 9 421
Number of patients with INR >6 79 23 24 0 6 132
% of patients with INR >6 29 29 44 0 67
Table III. The number of patients with INR > 6 
in various CYP2C9 genotype groups
Figure 1. CYP2C9 genotypes and the acenocoumarol dose
Cyp2C9 genotypes 1/1 1/2 1/3 2/2 2/3 3/3
number of patients 276 78 55 3 9 0




















* – p <0.05
** – p <0.001
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occurrence of bleeding complications, careful
monitoring of treatment is required. The widespread
use of pharmacogenetic examinations raises the
question of whether knowing the genotype could
improve the quality and accuracy of anticoagulation.
In this study, the CYP 2C9 genotype of 421 patients
taking acenocoumarol was determined and correlations
of the genotype with clinical data were analysed. The
frequency distribution of the CYP2C9 alleles in the
studied group was similar to that reported by others [3].
In our study, the acenocoumarol dose of patients
bearing alleles with reduced enzymatic activity
(CYP2C9*2 and*3) was significantly lower, which proves
that genotype is an important determinant of the
optimal dose, similarly as in the case of warfarin.
However, in patients with a daily dose <2 mg the
occurrence of INR values >6 was high. We also found
a correlation between genotype and minor rather than
major bleeding complications.
Taking all these findings into consideration, we believe
that the usual method of accurate anticoagulation
monitoring might be sufficient; however, a prospective,
large, randomised study is required to establish whether
routine genotyping before the initiation of oral
anticoagulant therapy would be cost-effective and could
provide a considerable benefit in the prevention of
significant bleeding. The demonstrated association
between minor bleeding and over-anticoagulation raises
the issue of the need for a cost-effectiveness analysis in
this field. The negative correlation with age and serum
creatinine directs particular attention to older people and
patients with impaired renal function. Tassies et al.
stated that in patients having other than homozygous
wild type genotype, the mean acenocoumarol dose was
lower, but the frequency of bleeding complications was
not higher [9].
Verstuyft et al. initially stressed the important role
of routine genotyping before the beginning of
anticoagulant treatment [10]. However, as time passed,
their view changed and in 2003 the same team
believed that in the case of over-anticoagulation
environmental factors played a more important role
than genetic ones [11].
Hermida et al. showed that the metabolism of
aconocoumarol depends less on genotype than does
that of warfarin. Thus, in cases with unstable warfarin
treatment, genotyping seems justified (12). In the work
of Laporte et al., there was no difference in the
effectiveness of anticoagulation in the case of
administering acenocoumarol or warfarin [13].
Evaluating the correlation between acenocoumarol
pharmacokinetics and genetic polymorphism, Thijssen
and Ritzen documented that the metabolism of
S-acenocoumarol is hardly influenced by the presence of
variant alleles, which is why routine genotyping is not
necessary. INR determination is a sensitive marker, and
in the case of overdose, even in the presence of allele *3,
the omission of the drug results in rapid elimination.
These authors believe that determination of the
genotype could help in special conditions only [8].
Similarly to our data, Visser et al. showed that
patients with one or more variant allele (s) required
a significantly lower dose of acenocoumarol compared
to wild-type allele patients [14]. Among 996 outpatients
attending an anticoagulation clinic, an increased risk of
bleeding was found in those having a variant allele of
CYP2C9. This risk was not present during the initiation
phase of the therapy [15]. Trying to investigate to what
extent CYP P450 2C9 genetic variability contributes to
the acenocoumarol pharmacodynamic response, Morin
et al. stated that this accounts for 14% of
inter-individual variability [16].
Study limitations
The major disadvantage of our study is that the
collection of data from medical history was retrospective,
based on the existing medical records and patient
history (the mean follow-up time was around 56 months,
the maximum about 30 years).
Conclusions
Based on the data of our 421 patients and surveying
the literature, the following conclusions can be
proposed:
1. The frequency distribution of the CYP2C9 alleles was
as reported by others.
2. The CYP2C9 polymorphism is the major determinant
of the acenocoumarol dose requirement.
3. The dose requirement decreases with age and renal
function impairment. 
4. In patients bearing variant alleles, the occurrence of
minor bleeding complications and an INR value >6 is
significantly more frequent than in other patients.
5. In patients with a lower acenocoumarol requirement,
caution is needed when initiating treatment.
6. Large, prospective, randomised trials are required to
answer the question of whether genotyping before the
initiation of anticoagulation therapy is cost-effective
and clinically valuable.
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Streszczenie
Wstęp: Doustne leki przeciwzakrzepowe, w tym acenokumarol, który jest jedynym antykoagulantem stosowanym na Wę-
grzech, charakteryzują się niskim współczynnikiem terapeutycznym i wysokim ryzykiem powikłań krwotocznych. Układ cyto-
chromu P450 (CYP2C9) bierze istotny udział w metabolizmie antykoagulantów doustnych. 
Cel pracy: Ocena wpływu polimorfizmu CYP2C9 na częstość występowania powikłań krwotocznych związanych ze stosowa-
niem acenokumarolu.
Metodyka: Grupa badana składała się z 421 chorych (183 mężczyzn, 238 kobiet, średni wiek 66,2±11,8 lat), u których stoso-
wano acenokumarol przez okres co najmniej 6 mies. przed przeprowadzeniem niniejszej analizy. Na podstawie wywiadu, danych
z historii choroby, badań laboratoryjnych i genetycznych dokonano retrospektywnej oceny zależności pomiędzy genotypem
a stosowaną dawką acenokumarolu i występowaniem powikłań krwotocznych. 
Wyniki: U 145 chorych, u których występowały allele o zmniejszonej aktywności (CYP2C9*2 lub *3) optymalna dawka ace-
nokumarolu była istotnie niższa niż u chorych z dzikim typem allelu (odpowiednio 2,12±0,96 mg/dobę vs 2,90±1,46 mg/dobę, 
p <0,001). Dawka dobowa acenokumarolu była najwyższa u chorych z dzikim typem allelu, pośrednia u chorych z CYP2C9*2,
a najniższa u nosicieli genu *3. Wartości INR >6 stwierdzano istotnie częściej u chorych, u których stwierdzano allele o zmniej-
szonej aktywności (p=0,021). Częstość występowania małych powikłań krwotocznych była istotnie wyższa u chorych, u których
stwierdzano allele o zmniejszonej aktywności (OR=1,99; CI=1,20–3,33, p <0,005), natomiast częstość występowania dużych po-
wikłań krwotocznych była podobna we wszystkich badanych podgrupach. Stwierdzono również umiarkowaną, ale istotną sta-
tystycznie ujemną korelację pomiędzy dawką acenokumarolu a wiekiem (r=–0,257) i stężeniem kreatyniny (r=–0,178).
Wnioski: Chorzy z obniżoną aktywnością enzymatyczną CYP2C9 wymagają mniejszych dawek acenokumarolu. U chorych z al-
lelami CYP2C9*2 i *3 częstość występowania małych powikłań krwotocznych i przypadki bardzo wysokich wartości INR były istot-
nie wyższe niż u pozostałych chorych, natomiast częstość występowania istotnych krwawień nie różniła się pomiędzy grupami.
Słowa kluczowe: doustne antykoagulanty, acenokumarol, cytochrom P450
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